Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more
Teva Pharmaceutical Industries Limited (TEVJF) - Net Assets
Latest net assets as of December 2025: $7.92 Billion USD
Based on the latest financial reports, Teva Pharmaceutical Industries Limited (TEVJF) has net assets worth $7.92 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($40.76 Billion) and total liabilities ($32.84 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.92 Billion |
| % of Total Assets | 19.42% |
| Annual Growth Rate | 13.5% |
| 5-Year Change | -29.6% |
| 10-Year Change | -77.38% |
| Growth Volatility | 27.66 |
Teva Pharmaceutical Industries Limited - Net Assets Trend (1985–2025)
This chart illustrates how Teva Pharmaceutical Industries Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Teva Pharmaceutical Industries Limited (1985–2025)
The table below shows the annual net assets of Teva Pharmaceutical Industries Limited from 1985 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.92 Billion | +38.39% |
| 2024-12-31 | $5.72 Billion | -29.61% |
| 2023-12-31 | $8.13 Billion | -6.50% |
| 2022-12-31 | $8.69 Billion | -22.71% |
| 2021-12-31 | $11.24 Billion | +1.65% |
| 2020-12-31 | $11.06 Billion | -26.57% |
| 2019-12-31 | $15.06 Billion | -4.63% |
| 2018-12-31 | $15.79 Billion | -15.74% |
| 2017-12-31 | $18.75 Billion | -46.43% |
| 2016-12-31 | $34.99 Billion | +16.93% |
| 2015-12-31 | $29.93 Billion | +28.14% |
| 2014-12-31 | $23.36 Billion | +3.18% |
| 2013-12-31 | $22.64 Billion | -1.01% |
| 2012-12-31 | $22.87 Billion | +2.35% |
| 2011-12-31 | $22.34 Billion | +1.55% |
| 2010-12-31 | $22.00 Billion | +14.24% |
| 2009-12-31 | $19.26 Billion | +17.72% |
| 2008-12-31 | $16.36 Billion | +18.90% |
| 2007-12-31 | $13.76 Billion | +23.11% |
| 2006-12-31 | $11.18 Billion | +84.73% |
| 2005-12-31 | $6.05 Billion | +12.05% |
| 2004-12-31 | $5.40 Billion | +63.82% |
| 2003-12-31 | $3.30 Billion | +79.69% |
| 2002-12-31 | $1.83 Billion | +32.65% |
| 2001-12-31 | $1.38 Billion | +19.94% |
| 2000-12-31 | $1.15 Billion | +55.33% |
| 1999-12-31 | $742.30 Million | +12.54% |
| 1998-12-31 | $659.60 Million | +7.64% |
| 1997-12-31 | $612.80 Million | +14.50% |
| 1996-12-31 | $535.20 Million | +31.31% |
| 1995-12-31 | $407.60 Million | +19.04% |
| 1994-12-31 | $342.40 Million | +27.81% |
| 1993-12-31 | $267.90 Million | +20.08% |
| 1992-12-31 | $223.10 Million | +21.91% |
| 1991-12-31 | $183.00 Million | +34.96% |
| 1990-12-31 | $135.60 Million | +13.57% |
| 1989-12-31 | $119.40 Million | +20.48% |
| 1988-12-31 | $99.10 Million | +71.45% |
| 1986-12-31 | $57.80 Million | +15.83% |
| 1985-12-31 | $49.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Teva Pharmaceutical Industries Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58413.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $21.67 Billion | 273.95% |
| Total Equity | $7.91 Billion | 100.00% |
Teva Pharmaceutical Industries Limited Competitors by Market Cap
The table below lists competitors of Teva Pharmaceutical Industries Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Emera Incorporated
NYSE:EMA
|
$15.79 Billion |
|
POP MART INT.GRP.DL-0001
F:735
|
$15.79 Billion |
|
H4W0
F:H4W0
|
$15.80 Billion |
|
Trimble Inc
NASDAQ:TRMB
|
$15.80 Billion |
|
Viatris Inc
NASDAQ:VTRS
|
$15.79 Billion |
|
Corem Property Group AB (publ)
ST:CORE-D
|
$15.76 Billion |
|
FinecoBank Banca Fineco S.p.A
PINK:FNBKY
|
$15.75 Billion |
|
Magna International Inc
NYSE:MGA
|
$15.74 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Teva Pharmaceutical Industries Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,373,000,000 to 7,911,642,000, a change of 2,538,642,000 (47.2%).
- Net income of 1,527,366,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 3,148,000,000.
- Other factors decreased equity by 2,136,724,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.53 Billion | +19.31% |
| Other Comprehensive Income | $3.15 Billion | +39.79% |
| Other Changes | $-2.14 Billion | -27.01% |
| Total Change | $- | 47.25% |
Book Value vs Market Value Analysis
This analysis compares Teva Pharmaceutical Industries Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 129.15x to 2.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.11 | $14.75 | x |
| 1986-12-31 | $0.13 | $14.75 | x |
| 1988-12-31 | $0.29 | $14.75 | x |
| 1989-12-31 | $0.35 | $14.75 | x |
| 1990-12-31 | $0.34 | $14.75 | x |
| 1991-12-31 | $0.44 | $14.75 | x |
| 1992-12-31 | $0.54 | $14.75 | x |
| 1993-12-31 | $0.63 | $14.75 | x |
| 1994-12-31 | $0.71 | $14.75 | x |
| 1995-12-31 | $0.83 | $14.75 | x |
| 1996-12-31 | $1.09 | $14.75 | x |
| 1997-12-31 | $1.25 | $14.75 | x |
| 1998-12-31 | $1.35 | $14.75 | x |
| 1999-12-31 | $1.51 | $14.75 | x |
| 2000-12-31 | $2.21 | $14.75 | x |
| 2001-12-31 | $2.53 | $14.75 | x |
| 2002-12-31 | $3.26 | $14.75 | x |
| 2003-12-31 | $5.58 | $14.75 | x |
| 2004-12-31 | $7.83 | $14.75 | x |
| 2005-12-31 | $8.87 | $14.75 | x |
| 2006-12-31 | $13.84 | $14.75 | x |
| 2007-12-31 | $16.53 | $14.75 | x |
| 2008-12-31 | $19.88 | $14.75 | x |
| 2009-12-31 | $21.45 | $14.75 | x |
| 2010-12-31 | $23.83 | $14.75 | x |
| 2011-12-31 | $24.85 | $14.75 | x |
| 2012-12-31 | $26.08 | $14.75 | x |
| 2013-12-31 | $26.55 | $14.75 | x |
| 2014-12-31 | $27.17 | $14.75 | x |
| 2015-12-31 | $34.45 | $14.75 | x |
| 2016-12-31 | $34.69 | $14.75 | x |
| 2017-12-31 | $17.09 | $14.75 | x |
| 2018-12-31 | $14.40 | $14.75 | x |
| 2019-12-31 | $12.81 | $14.75 | x |
| 2020-12-31 | $9.16 | $14.75 | x |
| 2021-12-31 | $9.28 | $14.75 | x |
| 2022-12-31 | $7.11 | $14.75 | x |
| 2023-12-31 | $6.71 | $14.75 | x |
| 2024-12-31 | $4.75 | $14.75 | x |
| 2025-12-31 | $6.80 | $14.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Teva Pharmaceutical Industries Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.31%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.18%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 5.15x
- Recent ROE (19.31%) is above the historical average (5.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 15.23% | 8.33% | 0.66x | 2.79x | $2.61 Million |
| 1986 | 25.61% | 10.60% | 0.98x | 2.47x | $9.02 Million |
| 1988 | 12.11% | 5.68% | 0.85x | 2.50x | $2.09 Million |
| 1989 | 14.15% | 6.01% | 0.98x | 2.40x | $4.96 Million |
| 1990 | 15.34% | 6.32% | 0.96x | 2.54x | $7.24 Million |
| 1991 | 12.99% | 7.25% | 0.87x | 2.07x | $5.46 Million |
| 1992 | 14.66% | 8.02% | 0.91x | 2.00x | $10.37 Million |
| 1993 | 21.50% | 11.45% | 0.89x | 2.10x | $30.75 Million |
| 1994 | 20.94% | 12.18% | 0.87x | 1.98x | $37.40 Million |
| 1995 | 19.81% | 11.95% | 0.77x | 2.16x | $39.51 Million |
| 1996 | 13.74% | 7.70% | 0.77x | 2.32x | $19.98 Million |
| 1997 | 16.58% | 9.09% | 0.94x | 1.94x | $40.30 Million |
| 1998 | 10.44% | 6.17% | 0.78x | 2.18x | $2.92 Million |
| 1999 | 15.87% | 9.19% | 0.75x | 2.31x | $43.60 Million |
| 2000 | 12.89% | 8.48% | 0.61x | 2.48x | $33.28 Million |
| 2001 | 20.15% | 13.39% | 0.60x | 2.51x | $140.14 Million |
| 2002 | 22.43% | 16.29% | 0.54x | 2.53x | $227.36 Million |
| 2003 | 21.01% | 21.09% | 0.55x | 1.80x | $362.06 Million |
| 2004 | 6.16% | 6.91% | 0.50x | 1.79x | $-207.09 Million |
| 2005 | 17.75% | 20.42% | 0.51x | 1.72x | $468.07 Million |
| 2006 | 4.90% | 6.49% | 0.41x | 1.84x | $-568.20 Million |
| 2007 | 14.22% | 20.75% | 0.40x | 1.71x | $579.60 Million |
| 2008 | 3.90% | 5.73% | 0.34x | 2.02x | $-995.00 Million |
| 2009 | 10.40% | 14.39% | 0.41x | 1.76x | $77.80 Million |
| 2010 | 15.18% | 20.66% | 0.41x | 1.78x | $1.14 Billion |
| 2011 | 12.43% | 15.07% | 0.37x | 2.26x | $539.50 Million |
| 2012 | 8.62% | 9.66% | 0.40x | 2.22x | $-313.80 Million |
| 2013 | 5.62% | 6.25% | 0.43x | 2.11x | $-987.50 Million |
| 2014 | 13.10% | 15.07% | 0.44x | 1.99x | $723.70 Million |
| 2015 | 5.33% | 8.08% | 0.36x | 1.82x | $-1.39 Billion |
| 2016 | 0.99% | 1.50% | 0.24x | 2.79x | $-3.00 Billion |
| 2017 | -93.70% | -72.66% | 0.32x | 4.07x | $-18.00 Billion |
| 2018 | -14.62% | -11.40% | 0.31x | 4.13x | $-3.62 Billion |
| 2019 | -7.15% | -5.92% | 0.29x | 4.11x | $-2.40 Billion |
| 2020 | -39.80% | -23.95% | 0.33x | 5.05x | $-4.99 Billion |
| 2021 | 4.06% | 2.63% | 0.33x | 4.64x | $-610.80 Million |
| 2022 | -29.80% | -15.77% | 0.34x | 5.57x | $-3.14 Billion |
| 2023 | -7.45% | -3.53% | 0.36x | 5.79x | $-1.31 Billion |
| 2024 | -30.50% | -9.91% | 0.42x | 7.32x | $-2.18 Billion |
| 2025 | 19.31% | 8.18% | 0.46x | 5.15x | $736.20 Million |
Industry Comparison
This section compares Teva Pharmaceutical Industries Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited (TEVJF) | $7.92 Billion | 15.23% | 4.15x | $15.79 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |